# Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

> **NCT00491816** · PHASE2 · UNKNOWN · sponsor: **University of Kansas Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Erlotinib with neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT00491816
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** 2014-12
- **Final completion:** 2017-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491816, "Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00491816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*